The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects

“…Taken together, these data provide important implications for the understanding of the beneficial effects of Q-compounds observed both in autoimmune disease [30,40,41] and cancer [61,62]. Both autoimmune diseases and the growth of solid tumors involve inflammation mediated by myeloid cells.…”

“…These compounds have shown efficacy in several mouse models of inflammatory autoimmune disease [29][30][31][32][33] and they are currently in clinical development for multiple sclerosis [34][35][36][37], systemic sclerosis and prostate cancer [38,39]. Recently, the S100A9 protein was identified as one molecular target of the Q-compound paquinimod (ABR-215757) [40].…”

Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice

“…It is possible that its efficacy is partly due to the effect on IL-23 expression. A new molecule laquinimod (ABR-215062) has been modified chemically from roquinimex and it has been favourable in the acute EAE of SJL/ N mice as well as in chronic EAE of B10.RIII strain of mice [32] and also warrants further research on of its effects on viral infections and on expression of cytokines.…”

Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: Block of initiation of proliferation of Gr-1+ cells

“…In preclinical settings 5757 and structurally related compounds have shown efficacy in several mouse models of T cell-dependent human inflammatory autoimmune disease ( [1][2][3][4], and unpublished data). This suggested to us that the 5757 treatment might target a common inflammatory mechanism(s) in the various disease models.…”

“…Previous reports have shown that quinoline-3-carboxamides ameliorate autoimmune disease in experimental models such as experimental autoimmune encephalomyelitis (EAE) [2,4]. It is well established that subcutaneous immunization with…”